Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
In clinical trials, treatment proved more effective than other therapies evaluated
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
ArisGlobal acquires Boehringer Ingelheim’s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment
GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation Protein Footprinting Systems.
Subscribe To Our Newsletter & Stay Updated
